DABIGATRAN
نویسندگان
چکیده
منابع مشابه
Dabigatran (Pradaxa).
Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.
متن کاملDabigatran-induced Exfoliative Esophagitis.
A 78-year-old-woman, with a history of non-valvular atrial fibrillation, had been taking dabigatran for twelve months and was referred to our hospital due to epigastralgia which was resistant to omeprazole administration. Esophagogastroduodenoscopy revealed longitudinal sloughing mucosal casts in the mid-esophagus (Picture 1, 2) without any remarkable findings in the esophagogastric junction, t...
متن کاملThe Dabigatran debate
In the June 2013 issue of this Journal, we described compelling evidence for the use of three novel anticoagulants, including Dabigatran, on the basis of recent large multi-centre trials. We acknowledged the approval of NOACs over warfarin in the ESC update and ACCP guidelines, and foresaw the greater usage of these newer, promising, therapies for stroke prevention in non-valvular atrial fibril...
متن کاملDabigatran and apolipoprotein B.
Dabigatran is the first of a series of new direct acting oral anticoagulants that was clinically introduced for the prevention of ischaemic stroke in patients with atrial fibrillation (AF). In the randomized evaluation of long-term anticoagulation therapy (RE-LY) study, dabigatran was shown to be superior or non-inferior to warfarin in preventing ischaemic stroke, depending on the dose administ...
متن کاملDabigatran monitoring made simple?
Haemost 2013; 110: 308-315. Dabigatran, an oral thrombin inhibitor, is licensed as an alternative to warfarin for stroke prevention in patients with atrial fibrillation. As the first of the new oral anticoagulants (NOACs) to gain approval for this indication, its use is increasing now that its safety has been confirmed using real-world data (1, 2), and clinical guidelines have given preference ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Prescribing Practice
سال: 2020
ISSN: 2631-8385,2631-8393
DOI: 10.12968/jprp.2020.2.11.564